• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Services
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development
  • One-Stop TIL Development
• CIK Therapy Development
  • One-Stop CIK Therapy Development
  • CIK Therapy Improvement

Allogeneic TCR-T Therapy Development Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Using autologous T-cell therapies for cancer treatment presents several challenges. These challenges include factors related to prior chemotherapies or allogeneic hematopoietic cell transplantation (HCT), which can affect the quantity and quality of the initial material. Additionally, there is uncontrollable variability between patients and prolonged waiting times due to global manufacturing processes. To solve the challenges in scalability and timely availability, Creative Biolabs offers allogeneic TCR-T therapy development services to accelerate your program.

TCR-T cell therapy

TCR-T cell therapy is a type of cellular immunotherapy for cancer that entails genetically modifying T cells to produce T cell receptors (TCRs) capable of recognizing specific tumor-associated antigens. This therapy enables T cells to identify and destroy cancer cells expressing these antigens, providing a promising treatment option for solid tumors. TCR-T cell therapy offers advantages such as recognition of multiple tumor antigens, independence from surface antigen limitations, enhanced specificity, potential for personalized treatment, and improved anti-tumor activity. At the same time, TCR-T cell therapy is facing some challenges including:

• Insufficient Activation of T Cells: Inadequate activation of T cells can lead to immune escape, reducing the efficacy of immunotherapy in certain patients.
• Selection of Target Antigen: Identifying suitable target antigens with high specificity and safety is a challenge, as not all tumor antigens are ideal for TCR-T cell therapy.
• Tumor Antigen Heterogeneity: Tumor cells exhibit antigenic heterogeneity, which can lead to the escape of some cells from specific antigen-targeted therapy, causing therapeutic resistance.
• TCR Affinity Control: Balancing the affinity of TCRs for antigens is crucial, as too low affinity may be ineffective, while too high affinity can lead to off-target toxicity and adverse events.
• Tumor Immune Escape: Tumor cells can evade immune responses, including TCR-T cell therapy, through mechanisms such as downregulation of target antigens, posing a challenge to treatment efficacy.

Fig 1. The structure of TCR-T cell.1

To enhance the effectiveness of TCR-T cell therapy, we may consider the following aspects:

• Optimizing Target Antigen Selection: Choosing target antigens with high specificity and safety to improve TCR-T cell recognition and efficacy.
• Controlling TCR Affinity: Balancing TCR affinity for antigens to enhance immune responses without causing off-target toxicity.
• Addressing Tumor Antigen Heterogeneity: Developing TCR-T cells that can target multiple antigens or tumor subclones to overcome tumor heterogeneity.
• Increasing Structural Affinity: Modifying TCR structures to improve antigen recognition and binding, enhancing anti-tumor activity.
• Incorporating CD4+ T Cells: Utilizing CD4+ T cells in combination with CD8+ T cells to promote T cell proliferation and enhance anti-tumor effects.

Allogeneic TCR-T Cell Therapy Development at Creative Biolabs

Creative Biolabs has established dedicated platforms aimed at enhancing your TCR-T cell therapy protocols. We are pleased to offer assistance in allogeneic TCR-T cell therapy. For more details, please explore:

• Non-viral Vector Delivery Cell Development Service
  Allogeneic T-cell therapy offers a promising approach by providing readily available off-the-shelf cell products that can be used in a broader patient population. The products can be well-characterized, generated in advance and stored in cell banks. Compared to autologous cell therapies, allogeneic cell therapies offer several advantages including:
  
  • Avoidance of interpatient variability: Allogeneic T-cell therapies help overcome the uncontrollable interpatient variability associated with autologous therapies.
  • Potential for broader applicability: Allogeneic T cell therapies can be used in a broader patient population, as they are not limited to individual patient characteristics.
  • Reduced waiting times: Allogeneic T-cell therapies can be administered more quickly to patients, as they do not require the lengthy manufacturing processes associated with autologous therapies.

Please contact us and we would be pleased to help you improve your program through allogeneic TCR-T cell therapy.

Reference

1. Liu, Y., et al. "TCR-T Immunotherapy: The Challenges and Solutions." Front Oncol. 11 (2022): 794183.